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Abstract
BACKGROUND—In 2016, the response to a yellow fever outbreak in Angola and the 
Democratic Republic of Congo led to a global shortage of yellow fever vaccine. As a result, a 
fractional dose of the 17DD yellow fever vaccine (containing one fifth [0.1 ml] of the standard 
dose) was offered to 7.6 million children 2 years of age or older and nonpregnant adults in a 
preemptive campaign in Kinshasa. The goal of this study was to assess the immune response to the 
fractional dose in a large-scale campaign.
METHODS—We recruited participants in four age strata at six vaccination sites. We assessed 
neutralizing antibody titers against yellow fever virus in blood samples obtained before 
vaccination and at 1 month and 1 year after vaccination, using a plaque reduction neutralization 
test with a 50% cutoff (PRNT50). Participants with a PRNT50 titer of 10 or higher were considered 
to be seropositive. Those with a baseline titer of less than 10 who became seropositive at follow-up 
were classified as having undergone seroconversion. Participants who were seropositive at 
baseline and who had an increase in the titer by a factor of 4 or more at follow-up were classified 
as having an immune response.
RESULTS—Among 716 participants who completed the 1-month follow-up, 705 (98%; 95% 
confidence interval [CI], 97 to 99) were seropositive after vaccination. Among 493 participants 
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who were seronegative at baseline, 482 (98%; 95% CI, 96 to 99) underwent seroconversion. 
Among 223 participants who were seropositive at baseline, 148 (66%; 95% CI, 60 to 72) had an 
immune response. Lower baseline titers were associated with a higher probability of having an 
immune response (P<0.001). Among 684 participants who completed the 1-year follow-up, 666 
(97%; 95% CI, 96 to 98) were seropositive for yellow fever antibody. The distribution of titers 
among the participants who were seronegative for yellow fever antibody at baseline varied 
significantly among age groups at 1 month and at 1 year (P<0.001 for both comparisons).
CONCLUSIONS—A fractional dose of the 17DD yellow fever vaccine was effective at inducing 
seroconversion in participants who were seronegative at baseline. Titers remained above the 
threshold for seropositivity at 1 year after vaccination in nearly all participants who were 
seropositive at 1 month after vaccination. These findings support the use of fractional-dose 
vaccination for outbreak control. (Funded by the U.S. Agency for International Development and 
the Centers for Disease Control and Prevention.)
YELLOW FEVER IS A MOSQUITO-BORNE VIral disease endemic to tropical and subtropical regions in 
Africa and the Americas. Infection with yellow fever virus can result in subclinical to severe 
illness, characterized by fever, jaundice, and hemorrhage. There were an estimated 51,000 to 
380,000 severe cases of yellow fever and 19,000 to 180,000 deaths in Africa in 2013.1 
Treatment is managed to address patients’ symptoms. However, the administration of a 
highly effective vaccine is the primary method for prevention and control. All currently used 
yellow fever vaccines are live attenuated viral vaccines derived from the 17D strain.2,3 
Nearly all studies have shown that one dose induces seroconversion in more than 98% of 
recipients, and protection is believed to be lifelong.2,4,5
In December 2015, a large yellow fever outbreak began in Angola and spread to the 
neighboring Democratic Republic of Congo (DRC). The outbreak resulted in 962 confirmed 
cases and more than 7000 suspected cases across the two countries.6 Each year, 6 million 
doses of yellow fever vaccine are maintained by the World Health Organization (WHO) and 
partners in a global stockpile that can be used for outbreak response at the request of 
countries with inadequate vaccine supply.7 However, the outbreaks in Angola and DRC used 
approximately 30 million doses and depleted the stockpile multiple times during 2016.6
Faced with substantial global supply issues, the WHO reviewed available evidence on dose-
sparing strategies for yellow fever vaccination, including four studies involving three cohorts 
of 175 to 749 healthy adult participants.8–12 Two of the three cohorts were limited to male 
participants. All the studies showed a robust immune response to fractional doses of yellow 
fever vaccine as small as one fifth to one tenth of the standard dose. On the basis of this 
evidence, the WHO concluded that a fractional dose of the yellow fever vaccine could be 
used in adults and in children 2 years of age or older in response to an emergency situation 
when the current vaccine supply was insufficient.12
To prevent the spread of yellow fever in Kinshasa, the government planned a preemptive 
campaign targeting approximately 7.6 million persons during a 10-day period.13 However, 
there was insufficient vaccine supply available to meet campaign needs. Thus, under 
guidance from the WHO, the government of the DRC implemented the campaign using a 
fractional dose of 17DD vaccine (Bio-Manguinhos) at one fifth (0.1 ml) of the standard dose 
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in all nonpregnant adults and in children 2 years of age or older in August 2016. We 
evaluated the immunologic response to this fractional-dose vaccine delivered in a large-scale 
vaccination campaign.
METHODS
STUDY PARTICIPANTS AND DESIGN
From August 17 through August 26, 2016, the campaign was conducted at 2404 vaccination 
sites in Kinshasa.13 We selected 6 vaccination sites across the three geographic sectors of 
Kinshasa on the basis of economically diverse catchment populations and logistic feasibility. 
Persons who presented for vaccination at one of these sites were approached for potential 
inclusion in a convenience sample for the study, with an equal number of participants from 
four age strata: 2 to 5 years, 6 to 12 years, 13 to 49 years, and 50 years or older. The cutoffs 
for these age strata were selected on the basis of data regarding immunologic response to the 
yellow fever vaccine and other vaccines.2,14
All the participants who received fractional-dose vaccination during the campaign were 
eligible for inclusion unless they reported having immunosuppression, egg allergies, a 
history of problems with venipuncture, plans to relocate from Kinshasa, or previous yellow 
fever vaccination within the preceding 2 months. Children under the age of 2 years and 
pregnant women were ineligible because they received full-dose vaccine according to the 
campaign operating procedures. The criteria for vaccine administration were determined by 
the public health authorities in the DRC. All the participants provided limited medical 
information and written informed consent to obtain blood samples. Parents or legal 
guardians provided written permission for participants who were 17 years of age or younger. 
Adolescents between the ages of 13 and 17 years also provided written assent.
STUDY OVERSIGHT
The study was sponsored by the U.S. Agency for International Development and the Centers 
for Disease Control and Prevention (CDC). The protocol (available with the full text of this 
article at NEJM.org) was approved by the medical ethics committee at the University of 
Kinshasa School of Public Health. In accordance with the human-subjects review procedures 
of the CDC, it was determined that the CDC was not formally engaged in human-subjects 
research. The study was designed and supervised by the authors, who vouch for the accuracy 
and completeness of the data and analyses and for the adherence of the study to the protocol.
BASELINE VISIT AND VACCINATION
From each participant, we collected data regarding basic demographic characteristics, 
history of yellow fever vaccination, and recent symptoms compatible with yellow fever 
disease (specifically, fever with jaundice). A phlebotomist obtained a baseline blood sample 
before vaccination. Campaign staff members then administered a subcutaneous dose of 
17DD yellow fever vaccine at one fifth of the standard dose (0.1 ml) to 764 participants from 
one of six lots: 253 participants received vaccine from lot 164VFC002Z, 104 from lot 
164VFC003Z, 138 from lot 164VFC004Z, 127 from lot 164VFC005Z, 38 from lot 
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164VFC007Z, and 94 from lot 164VFC008Z; no lot number was recorded for doses 
administered to 10 participants.
The 17DD vaccine was recommended by the WHO for use in the campaign on the basis of 
availability, clinical trial data indicating seroresponse to fractional doses, and 5 years of 
batch-release data.8–10,15 According to these data, one fifth of a dose of the average batch 
potency had 8709 IU of vaccine per dose, and one fifth of a dose of minimum batch potency 
had 2692 IU per dose. Both of these doses were above the minimum vaccine potency (1000 
IU per dose) set by the WHO.16 The vaccine was packaged in standard 10-dose vials, which 
resulted in the use of each vial for approximately 50 fractional doses.13 Vaccination was 
observed by study staff members to ensure receipt of the dose. Adverse events after 
immunization were monitored as part of the campaign procedures rather than as part of this 
investigation.
FOLLOW-UP AND TESTING PROCEDURES
At 28 to 35 days after vaccination (1-month follow-up) and at 12 to 13 months (1-year 
follow-up), participants who returned to the health center were asked about yellow fever 
symptoms and receipt of medications or medical treatment during the interval between 
visits. A blood sample was obtained. Female participants of reproductive age were also 
asked about the date of the last menstrual period or whether they had subsequently 
determined that they were pregnant at the time of vaccination.
Blood samples that were obtained before vaccination and after vaccination were kept in 
temperature-controlled coolers during the day and transported each afternoon to Institut 
National de Recherche Biomedicale, where they were centrifuged and serum was aliquoted 
into cryovials and stored at −20°C. Serum samples were then shipped to the CDC Arbovirus 
Diseases Laboratory in Fort Collins, Colorado, where paired baseline and follow-up samples 
were tested for the presence of neutralizing antibodies against yellow fever virus with the 
use of the plaque reduction neutralization test with a cutoff of 50% (PRNT50) and a cutoff of 
90% (PRNT90), as described previously.17 Here, we report PRNT50 titers, since this cutoff is 
routinely used in vaccination trials of flavivirus vaccines and is recommended by the WHO 
for establishing sufficient virus-neutralizing antibody in the serum in vaccine 
immunogenicity studies conducted by vaccine manufacturers.16,18,19
Participants with a PRNT50 titer of 10 or higher in their sample at baseline were considered 
to be seropositive. Those who had a baseline PRNT50 titer of less than 10 and who were 
identified as being seropositive at the 1-month follow-up were classified as having 
undergone seroconversion. Participants who were seropositive at baseline and had an 
increase in the titer by a factor of 4 or more at the 1-month follow-up were classified as 
having had an immune response to vaccination.
Participants who were seronegative (PRNT50 titer, <10) at 1 month after vaccination were 
offered revaccination with the full dose (0.5 ml) at 1 year. A blood sample was obtained 
from these participants before revaccination and at 28 to 35 days after their revaccination. 
The titer of the blood sample that was obtained just before revaccination was used to 
determine the participant’s immune status at the 1-year follow-up.
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STATISTICAL ANALYSIS
We determined that a sample of 190 participants in each of four age groups (total, 760) 
would allow for an estimation of the immune response in each group, based on an estimated 
rate of immune response of 92% among the participants, with a 95% Wald confidence 
interval of ±5% and an attrition rate of 40%. All the participants who had baseline and 
follow-up samples were included in the 1-month analyses. Only the participants who were 
included in the 1-month analysis were eligible for inclusion in the 1-year follow-up analysis.
Estimated proportions and 95% confidence intervals were calculated with the use of the 
Wilson method. We compared the proportion of participants who had undergone 
seroconversion in groups according to age and sex using Fisher’s exact test. For analyses of 
immune response in participants who were seropositive at baseline, three subgroups of 
baseline PRNT50 titers were created: from 10 to 40, from 80 to 320, and 640 or higher. We 
assessed the association between the baseline-titer subgroup and the immune response using 
the Cochran–Armitage test for trend. Differences in immune response according to age 
group and sex were adjusted for baseline titer subgroups with the use of the Cochran–
Mantel–Haenszel test. We used the Kruskal–Wallis test and Wilcoxon rank-sum test to 
compare the distributions of titers. Bonferroni corrections were used with pairwise 
comparisons (alpha level, 0.05; adjusted alpha level, 0.008).
RESULTS
PARTICIPANTS
Of the 863 persons who were screened, 790 met the eligibility criteria, and 764 were 
enrolled; 716 (94%) completed the 1-month follow-up visit, and 684 (90%) completed the 1-
year follow-up visit (Fig. 1). Overall, 89 to 98% of the participants in each of the four age 
groups completed the initial follow-up. Of the participants who attended the 1-month follow-
up, 50% were female, and 79 (11%) reported having received previous yellow fever 
vaccination. All but 5 of those reporting previous vaccination were children 12 years of age 
or younger (Table 1). A history of previous vaccination was based primarily on oral report. 
None of the participants who had completed follow-up reported having had symptoms 
compatible with yellow fever after vaccination. The characteristics of participants with 1-
year follow-up data were similar to those of the participants with 1-month follow-up data.
VACCINE RESPONSE IN THE OVERALL POPULATION
Of the 716 participants, 705 (98%; 95% confidence interval [CI], 97 to 99) were seropositive 
after vaccination (Table 2). The proportion who were seropositive did not differ significantly 
according to age or sex.
Of the 684 participants who completed the 1-year follow-up, 666 (97%; 95% CI, 96 to 98) 
were seropositive. These participants included 664 who had been seropositive at 1 month 
and 2 participants who had been seronegative at 1 month but were seropositive at 1 year 
before subsequent revaccination. All 11 participants who were seronegative at 1 month 
either underwent seroconversion (9 participants) or had an immune response (2 participants) 
after receiving the supplementary full dose of yellow fever vaccine. There was no significant 
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association between the proportion who were seropositive at 1 year and either age or sex 
(Table 2).
VACCINE RESPONSE AMONG PARTICIPANTS WHO WERE SERONEGATIVE AT BASELINE
A total of 493 participants (69%) were seronegative for neutralizing antibodies against 
yellow fever at baseline (Table 3). Among these participants, seroconversion at 1 month was 
reported in 482 (98%; 95% CI, 96 to 99). The between-group differences in seroconversion 
were not significant according to age (P = 0.06). At the 1-month follow-up, participants 
between the ages of 13 and 49 years had a significantly higher geometric mean titer (2255; 
95% CI, 1604 to 3171) than the participants in all other age groups; children between the 
ages of 2 and 5 years had the lowest geometric mean titer at 487 (95% CI, 293 to 810). The 
seroconversion rate among male participants (99%; 95% CI, 97 to 100) was significantly 
higher than that among female participants (96%; 95% CI, 93 to 98) (P = 0.03). However, 
the geometric mean titers for male participants and female participants did not differ 
significantly (P = 0.61). Among the 5 female participants of reproductive age who did not 
undergo seroconversion, none were pregnant on the basis of reports of menstruation in the 
interval between vaccination and their subsequent follow-up visits.
Among the 475 participants who were seronegative at baseline and completed the 1-year 
follow-up, 457 (96%, 95% CI, 94 to 98) were seropositive (Table 3). Seropositivity at 1 year 
did not differ significantly according to age group (P = 0.11) or sex (P = 0.15). The 
distribution of titers at 1 year remained significantly different according to age group 
(P<0.001), with the highest titers seen in participants between the ages of 13 and 49 years 
and those who were 50 years of age or older. The difference in the distribution of titers 
according to sex was not significant (P = 0.46).
VACCINE RESPONSE AMONG PARTICIPANTS WHO WERE SEROPOSITIVE AT BASELINE
At baseline, 223 participants (31%) were seropositive for neutralizing antibodies against 
yellow fever virus (Table 3). In this subgroup, an immune response (titer of ≥4 times the 
baseline value) was elicited in 148 (66%; 95% CI, 60 to 72). There was an inverse 
relationship between a participant’s baseline titer and the likelihood of having an immune 
response at 1 month (P<0.001) (Fig. 2A). A total of 95% of the participants with a titer of 10 
to 40 had an immune response, as compared with only 15% of the participants who had a 
titer of 640 or higher at baseline. An anamnestic response was more notable among those 
with a lower baseline titer (Fig. 2B).
Among the participants who were seropositive at baseline, there was no significant between-
group difference in the proportion of male participants and female participants who had an 
immune response at 1 month (P = 0.74). However, there was a significant difference among 
age groups, even after adjustment for the baseline titer subgroup (P<0.001); only 33% (95% 
CI, 20 to 50) of the participants who were at least 50 years of age had an immune response 
(Table 3).
Among the 209 participants who were seropositive at baseline and completed the 1-year 
follow-up, all (100%; 95% CI, 98 to 100) remained seropositive. There was no significant 
difference in the distribution of titers at follow-up according to age group at 1 month (P = 
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0.16) or at 1 year (P = 0.98). Similarly, there was no significant difference in the distribution 
of titers at follow-up according to sex at 1 month (P = 0.71) or 1 year (P = 0.68) (Table 3).
DISCUSSION
In our study, which was conducted during a mass vaccination campaign that used one fifth 
of the standard dose of the 17DD yellow fever vaccine, we found that detectable antibodies 
against the yellow fever virus had developed in 98% of the participants by 1 month after 
vaccination. Furthermore, 97% of the participants were seropositive at 1 year after receipt of 
the fractional dose. These rates suggest that the use of fractional-dose vaccination is a viable 
approach for providing immunity and thus containing yellow fever outbreaks. These findings 
are important, given the ongoing risk of outbreaks of yellow fever globally, as shown during 
the 2017–2018 outbreak in Brazil, in which more than 21 million doses of yellow fever 
vaccine were administered to control the epidemic near many large population centers.20
The proportion of participants who underwent seroconversion was similar to that seen 
among full-dose vaccine recipients, in whom more than 98% underwent seroconversion in 
other studies.2 Our results are also similar to those seen in other studies of fractional-dose 
vaccination against yellow fever, in which participants have received as little as one fifth to 
one tenth of the standard dose.8–11 The previously published studies were performed in well-
controlled clinical trials involving healthy, mostly male adults. In contrast, our cohort 
included children (≥2 years of age) and adults of both sexes, and the vaccine was 
administered in a mass campaign setting. Given the campaign setting, it is notable that our 
results were similar to those in the controlled studies.
In 2003 in the DRC, yellow fever vaccine was introduced into the childhood vaccination 
program and is administered to children at the age of 9 months. In the 10 years before the 
initiation of our study, rates of vaccine coverage ranged from 50 to 70%.21 The routine use 
of yellow fever vaccine probably accounts for our finding that children 12 years of age or 
younger had a higher rate of baseline seropositivity than participants in the other age groups. 
Overall rates of seroconversion and immune response at 1 month did not vary significantly 
across age groups, except for participants who were 50 years of age or older; participants in 
this age group were less likely than those in other age groups to have an immune response to 
the vaccine if they had neutralizing antibodies at baseline.
However, we did see significant differences in follow-up geometric mean titers at 1 month 
and at 1 year according to age group among participants who were seronegative at baseline. 
Children who were under 13 years of age and who had been seronegative at baseline had a 
lower geometric mean titer at follow-up than participants who were 13 years of age or older, 
particularly at 1 year. This observation is consistent with data from several trials of yellow 
fever vaccines that indicated a lower immunologic response to vaccination among children 
than among adults.5 Initially after yellow fever vaccination, the geometric mean titer was 
lower among adults who were 50 years of age or older than among younger adults, a finding 
that has been observed for yellow fever vaccines and other vaccines.2,14,22 However, at 1 
year after vaccination, the titers in the older age group were similar to those in younger 
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adults, which suggests a different initial profile for antibody response but an overall good 
response to the fractional-dose vaccine.
Although we found a rate of seroconversion among female participants that was slightly but 
significantly lower than that among male participants, the geometric mean titers at both 
follow-up visits were similar. A slightly greater immunologic response to the vaccine among 
male participants has also been reported in trials in which the full-dose yellow fever vaccine 
was used,23–25 which suggests that the observed difference was not unique to the fractional 
dose.
It is unknown whether long-term antibody persistence will differ between fractional and full-
dose administration of yellow fever vaccine. We found that almost all the participants who 
received the fractional dose in our investigation were seropositive for yellow fever 
neutralizing antibodies at 1 year after vaccination. Furthermore, recent data from de 
Menezes Martins et al.26 showed high rates of detectable antibodies 8 years after the 
administration of various fractional doses, and Roukens et al.27 found similarly high rates of 
detectable antibodies at 10 years after vaccination among participants who had received a 
one-fifth dose intradermally and among those who had received a full dose subcutaneously. 
These findings suggest that immunity to fractional doses will probably persist for years.
Our study has several limitations. We did not include a control group of participants who 
received a full dose of yellow fever vaccine because of technical and ethical issues, so we 
could not directly compare the immune response after the fractional dose with that after a 
full dose. Also, the use of PRNT50 titers may have caused incorrect classification of 
participants with low titers as being seropositive for neutralizing antibodies against the 
yellow fever virus when in fact the titer was due to cross-reactive antibodies. However, since 
serum samples were obtained from each participant both before vaccination and after 
vaccination, the specific response to the vaccine could still be assessed. We did not calibrate 
the yellow fever antibody titers using an international reference preparation, which makes it 
difficult to compare our titers with those obtained in other studies of fractional-dose 
vaccination.17 International standardization of testing results for yellow fever has only 
recently been recommended, so very few data have been generated. The use of PRNT titers 
was preferred for this study to allow for comparison with much of the published data. We 
did not collect safety data during this evaluation. However, the adverse-event monitoring 
systems that were in place for the campaign did not identify any acute signals of concern 
associated with fractional-dose vaccination.28 Enhanced surveillance and community-based 
pharmacovigilance both detected approximately 0.5 serious adverse events per 100,000 
doses after the campaign,13,29 a rate that is similar to that after full-dose campaigns 
conducted in West Africa.30 Finally, we could not formally assess the effectiveness of the 
fractional dose with regard to preventing viral transmission during the outbreak, since the 
outbreak was waning at the time of the campaign. However, no new confirmed cases of 
yellow fever were detected in Kinshasa immediately after the campaign despite ongoing 
surveillance.
In conclusion, we found that the immunologic response to a fractional dose of the 17DD 
yellow fever vaccine was appropriate for a response to a yellow fever outbreak among 
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children 2 years of age or older and among nonpregnant adults. Additional studies are 
needed to determine whether fractional-dose vaccination provides adequate seroprotection in 
children under the age of 2 years, in pregnant women, and in persons who are infected with 
the human immunodeficiency virus.12 In addition, future studies need to verify that similar 
results are obtained with other 17D-derived yellow fever vaccines (17D-204 and 17D-213) 
and in populations with differing exposures to flaviviruses. Finally, additional studies with 
longer-term follow-up are needed to understand whether persons who receive fractional 
doses of yellow fever vaccine need to be revaccinated in order to sustain immunity to yellow 
fever virus.
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Figure 1. Enrollment and Follow-up.
Of the 40 eligible participants who were excluded from the 1-month analysis, 21 (52%) were 
female. Of the excluded participants, 20 (50%) were between the ages of 2 and 5 years, 4 
(10%) were between the ages of 6 and 12 years, 7 (18%) were between the ages of 13 and 
49 years, and 9 (22%) were 50 years of age or older. Investigation by the Ministry of Health 
determined that the single death that occurred between enrollment and 1-month follow-up 
was related to a cardiac event and not to vaccination. Of the 32 participants who were 
excluded from the 1-year analysis, 20 (63%) were female; 11 (34%) were between the ages 
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of 2 and 5 years, 6 (19%) were between the ages of 6 and 12 years, 5 (16%) were between 
the ages of 13 and 49 years, and 10 (31%) were 50 years of age or older. None of the 5 
deaths that occurred between the 1-month and 1-year follow-up were determined to be 
related to the yellow fever vaccination.
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Figure 2. Immune Response and Geometric Mean Titer at 1-Month Follow-up among 223 
Participants Who Were Seropositive at Baseline.
Panel A shows the proportion of participants who had an immune response 1 month after 
fractional-dose vaccination against yellow fever, according to the geometric mean titer of 
neutralizing antibodies at baseline. Panel B shows the geometric mean titer at 1-month 
follow-up according to the titer at baseline. In both panels, I bars indicate 95% confidence 
intervals. Data regarding the geometric mean titer at 1-year follow-up are provided in Figure 
S1 in the Supplementary Appendix.
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e 
pa
rti
ci
pa
nt
s w
ho
 w
er
e 
50
 y
ea
rs
 o
f a
ge
 o
r o
ld
er
 w
er
e s
ig
ni
fic
an
tly
 le
ss
 li
ke
ly
 to
 h
av
e 
an
 im
m
un
e 
re
sp
on
se
 th
an
 w
er
e 
th
e 
pa
rti
ci
pa
nt
s i
n 
al
l o
th
er
 a
ge
 g
ro
up
s.
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